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Summary
Background and objective Kisspeptin stimulates hypothala-
mic GnRH secretion resulting in gonadotrophin release and has
potential as a future therapeutic. Chronic subcutaneous infusion
of kisspeptin via a pump (similar to an insulin pump) may pro-
vide an alternative route of administration in the future. We
investigated for the first time in humans, the gonadotrophin
response to subcutaneous (SC) infusions of kisspeptin-54 in
healthy women. Women are markedly more responsive to
exogenous kisspeptin in the late follicular phase preovulation
when oestradiol levels are naturally high. Therefore, we further
investigated whether there was a correlation between baseline
oestradiol levels and LH response to kisspeptin.
Design and patients A prospective, single-blinded placebo-
controlled study. Healthy women (n = 4) received an 8-h SC
infusion of kisspeptin-54 01, 03 or 10 nmol/kg/h or saline in
the early follicular phase of 4 separate menstrual cycles. Gon-
adotrophins and oestradiol were measured every 10 min during
the infusions.
Results SC infusion of kisspeptin-54 increased LH and FSH.
The LH response to SC infusion of kisspeptin-54 (03 and
10 nmol/kg/h) positively correlated with baseline oestradiol
levels (P < 0001). Further statistical analyses showed that in the
10 nmol/kg/h group, a 100pmol/l rise in baseline oestradiol was
associated with a 10 IU/l increase in LH.
Conclusions Kisspeptin administered via a SC infusion could
be a viable future therapeutic route of administration for
patients with infertility. Baseline oestradiol levels may be an
important determinant of the gonadotrophin response to kis-
speptin treatment in women and should be taken into consider-
ation when evaluating gonadotrophin response.
(Received 25 June 2015; returned for revision 17 August 2015;
finally revised 7 October 2015; accepted 6 November 2015)
Introduction
Kisspeptin is a recently discovered hypothalamic hormone that is
crucial for puberty and reproduction.1,2 Kisspeptin stimulates the
hypothalamo-pituitary–gonadal (HPG) axis by acting on kisspep-
tin receptors on GnRH neurons resulting in GnRH release 3,4 and
thus is emerging as a novel therapeutic agent. Current treatments
for infertility include GnRH and gonadotrophins5; however, there
is potential for overstimulation of the HPG axis.6 Response to
kisspeptin may be more physiological than direct pituitary
stimulation as the effects of kisspeptin are limited by a patient’s
endogenous GnRH reserve.4,7
Kisspeptin peptides which stimulate gonadotrophin release
have a short half-life (278 min for kisspeptin-54 and 4 min for
kisspeptin-10).8,9 A number of recent studies have administered
kisspeptin to humans either intravenously (IV) or subcuta-
neously (SC).10 However, if kisspeptin is to be administered at
home as a potential therapeutic to patients, then either SC bolus
injections or SC infusion via a pump are possible routes of
administration. Insulin pumps are now used routinely for the
treatment of patients with type 1 diabetes.11 Therefore, pump
administration (i.e. SC infusion) of kisspeptin may be an alter-
native treatment modality as it could be given for prolonged
periods and be managed at home by the patient. However, no
previous study has investigated the gonadotrophin response to
SC infusion of kisspeptin in humans.
Administration of kisspeptin continuously via a SC pump
could result in desensitization of kisspeptin receptors (tachyphy-
laxis) and hence a reduction in gonadotrophins. Twice-daily
injections of kisspeptin-54 to women with hypothalamic
amenorrhoea resulted in tachyphylaxis.12 However, intravenous
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infusions of kisspeptin-54 resulted in a rise in LH pulsatility
over the 8-h infusion period.13 Thus, using smaller doses of kis-
speptin administered over a prolonged period, this may be effec-
tive in achieving a sustained and meaningful rise in
gonadotrophins but avoiding tachyphylaxis.
To evaluate this route of administration further, this clinical
study investigated for the first time in humans the effect of SC
infusions of kisspeptin-54 on gonadotrophin response in the
early follicular phase of the menstrual cycle.
Interestingly, women are markedly more responsive to kis-
speptin during the preovulatory phase of the menstrual cycle
compared with the early follicular phase.9,14 High oestradiol
levels are observed in the preovulatory phase compared with
the early follicular phase of the menstrual cycle, and this could
be a contributing factor to the differences seen in gonadotro-
phin response to exogenous kisspeptin in different phases of
the menstrual cycle in women. Studies in vitro and in vivo have
shown that GnRH stimulation by kisspeptin in the presence of
oestradiol is important and lack of oestradiol reduces the
secretion of kisspeptin-induced GnRH and subsequent
gonadotrophins.15–17 George et al. showed that post-
menopausal women were much more responsive to IV kisspep-
tin-10 than those taking sex steroid contraception or those in
the follicular phase of the menstrual cycle, indicating that per-
haps there is a difference in women with cyclically higher or
lower sex steroids compared with exogenous sex steroids or
postmenopausal low sex steroids.18
Chan et al. showed that women are least responsive to kis-
speptin in the early follicular phase when oestradiol is at its low-
est and despite increasing the dose of kisspeptin the LH
response did not alter.14 We proposed to further examine the
role of oestradiol in the LH response to kisspeptin by investigat-
ing whether a participant’s individual baseline oestradiol level
correlated with their LH response to kisspeptin administration.
Methods
Ethics
Ethical approval was granted by the Hammersmith, Queen
Charlotte’s and Chelsea Hospitals Research Ethics Committee,
London. The study was performed in accordance with the Dec-
laration of Helsinki.
Subjects
Healthy female volunteers aged between 18 and 38 years old
were recruited from local newspaper advertisements. They
underwent a detailed medical evaluation as part of the pre-
study screening to assess their suitability. The screening visit
involved obtaining informed consent, a medical history, medi-
cation history, clinical examination, electrocardiogram and
blood tests to test the following: full blood count, renal profile,
liver profile, bone profile, random glucose, thyroid profile,
PRL, LH, FSH, oestradiol, testosterone and SHBG. Participants
were recruited who fulfilled the following criteria: regular men-
strual cycles, no known medical problems or allergies, no med-
ication use, no oral contraceptive use in the preceding
4 months, no recreational drug use and no previous research
study participation or blood donation in the last 3 months.
Clinical examination, electrocardiogram and blood testing were
all normal. Four participants were recruited into the study.
Their ages, weight, BMI, mean baseline oestradiol and mean
menstrual cycle length are given in Table 1.
Protocol. The subjects were blinded but not the investigators.
The studies were conducted during the early follicular phase
(day 2–6) of the subject’s menstrual cycles. Each participant
attended for a total of four study visits (each study day was
carried out in a separate menstrual cycle) and received a
different treatment at each visit (saline or kisspeptin-54 at one
of three doses tested) Subjects were asked to refrain from
strenuous exercise, sexual activity and alcohol consumption for
the 24-h period preceding each study visit.
Studies were conducted in our clinical investigation unit, and
Fig. 1 shows a summary of the protocol for each study visit.
Subjects arrived in the morning and were cannulated in both
forearms and asked to lie supine. Baseline blood sampling was
performed and 30 min later an infusion of vehicle (09% saline)
or SC kisspeptin-54 was started and continued for 8-h. Ten
minutely blood sampling was then commenced for the duration
of the 8-h infusion until 480 min to measure gonadotrophins
and oestradiol. Blood samples were collected in plain serum
vacutainer tubes and were allowed to clot prior to centrifugation
and separation of the serum. The samples were centrifuged at
1350 g for 10 min, separated and then frozen at 20° until
analysed.
Table 1. Characteristics of participants. The demographics of the participants are shown. The weight and baseline oestradiol levels of each participant from
their 4 study visits were averaged and are shown below as mean weight and mean baseline oestradiol. All mean results are presented as data  SEM
Participant no. Age (years)
Mean
weight (kg) Height (cm) BMI
Mean baseline
LH (IU/l)
Mean baseline
FSH (IU/l)
Mean baseline
oestradiol (pmol/l)
Mean menstrual
cycle length (days)
1 3492 646 166 234 569  064 253  022 5809  1327 323  10
2 3775 654 175 214 210  061 432  076 903  255 266  19
3 2058 674 170 233 588  088 620  091 2086  357 248  09
4 2217 746 178 235 488  070 464  033 1155  219 36  04
Mean 2886  47 680  23 1723  26 229  05 464  051 442  044 2490  598 299  28
© 2015 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
Clinical Endocrinology (2015), 0, 1–7
2 S. Narayanaswamy et al.
Three doses of kisspeptin-54 were investigated: 01, 03 and
10 nmol/kg/h. The doses chosen have been previously shown to
cause a rise in LH in healthy women following a single SC injec-
tion.19 Kisspeptin was administered subcutaneously into the
abdomen, and the infusion rate of peptide was doubled in the
first 30 min in order to achieve steady-state plasma levels during
the infusion period.20 Therefore, total doses of 085, 255 or
850 nmol/kg peptide were administered during 8-h infusions
with maintenance administration rates of 010, 030 or
100 nmol/kg/h, respectively. Participants had their blood pres-
sure and pulse recorded on arrival and at regular intervals
throughout the study.
Peptide. Human kisspeptin-54 was synthesized by Bachem AG
(Liverpool, UK) and further purified and tested as previously
described.8,9 Vials of freeze-dried kisspeptin-54 were stored at
20° and then reconstituted with 09% saline. The rate of
infusion was calculated as per the weight. A set amount of the
peptide solution from the reconstituted vial was transferred into
the 50-ml syringe containing 09% saline.
Analysis. Frozen samples were defrosted and analysed for
measurement of LH, FSH and oestradiol using automated
chemiluminescent immunoassays (Abbott Diagnostics,
Maidenhead, UK). Reference ranges for females were as follows:
LH 2–10 IU/l (follicular), FSH 15–8 IU/l (follicular and luteal)
and oestradiol <300pmol/l (early follicular). The respective
intra-assay and interassay coefficients of variation for each assay
were as follows: 41 and 34% (LH); 41 and 30% (FSH); 33%
and 30% (oestradiol). Analytical sensitivities were as follows:
05 IU/l (LH), 005 IU/l (FSH); 37 pmol/l (oestradiol).
Data analysis/statistical analysis. The data were analysed by a
statistician, P.B. To allow for the repeat measurements over time
and multiple comparisons between groups, the analysis was
performed using multilevel linear regression with Bonferroni
adjustment. Linear regression analysis was also used to
investigate any correlation between baseline oestradiol levels and
LH response to kisspeptin-54 at the different doses. In all cases,
P < 005 was considered statistically significant and data are
presented as mean  SEM. J.D.V. used a previously described,
blinded deconvolution method with 93% sensitivity and
specificity to analyse LH pulsatility.21
Results
Table 1 shows the participant’s characteristics; mean age
2886  47 years and mean BMI 229  05. No participants
reported any adverse effects. There were no changes in heart rate
or blood pressure during the studies (results not shown).
SC infusion
At all doses tested in this study, kisspeptin-54 caused a rise in
serum LH. Fig. 2a shows a time profile of the 8-h study, present-
ing the mean LH results at each time point from the four partici-
pants receiving the same treatment (vehicle or SC kisspeptin-54
01, 03, 10 nmol/kg/h doses). Both vehicle and the 01 nmol/kg/
h group had slight increases in LH values over time (P = 032,
01 nmol/kg/h vs vehicle), whereas the increase in LH was much
greater for the 03 and 10 nmol/kg/h groups and this was found
to be highly statistically significant when compared with vehicle
for both the 03 and 10 nmol/kg/h groups (P < 0001).
Fig. 2b shows a graphical representation of the mean LH over
the study period from the data presented in Fig. 2a.
Fig. 3a shows the time profile of the study with mean FSH
values for each time point from the 4 participants receiving the
same treatment. There was a significant increase in serum FSH
with all doses of SC kisspeptin-54 when compared with vehicle
(P < 005, 01 nmol/kg/h vs vehicle; P < 0001, 03 nmol/kg/h vs
vehicle; P < 0001, 10 nmol/kg/h vs vehicle). Fig. 3b shows the
mean serum FSH for each intervention over the study period
from the data presented in Fig. 3a.
Fig. 4 shows the individual time profiles of the 4 participants
receiving infusions of vehicle and SC kisspeptin-54 at 3 doses.
LH pulsatility was formally analysed by a deconvolution
method and although the number of LH pulses increases with
increasing doses of kisspeptin-54 (Fig. S1A), this difference did
not reach statistical significance (number of LH pulses per 8-h:
43  11, vehicle; 55  18 kisspeptin-54 01 nmol/kg/h;
60  13 kisspeptin-54 03 nmol/kg/h; 60  07 kisspeptin-54
10 nmol/kg/h). The LH pulse amplitude (Fig. S1B) did not
Infusion of vehicle or SC kisspeptin-54 
0 1 2 3 4 5 6 7 8
Blood sampling every 10 min for LH, FSH and oestradiol
End
Time 
(h)
Start
–0·5
Baseline 
blood 
sample
Fig. 1 Study protocol diagram. Healthy women (n = 4) received a single 8-h infusion of saline or SC kisspeptin-54 01, 03 or 10 nmol/kg/h in the
early follicular phase (day 2–6 of the menstrual cycle) of four separate menstrual cycles in random order. Each participant underwent a baseline blood
sample 30 min prior to the kisspeptin infusion or vehicle. The infusion was started at t = 0 h and continued for 8-h. Blood samples were taken every
10 min (upward arrows) for the duration of the 8-h study to measure LH, FSH and oestradiol.
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show any difference between the dosing groups (mean LH pulse
amplitude in IU/l: 541  089, vehicle; 810  211 kisspeptin-
54 01 nmol/kg/h; 731  167 kisspeptin-54 03 nmol/kg/h;
692  176 kisspeptin-54 10 nmol/kg/h).
Baseline oestradiol vs LH response to kisspeptin
administration
Using regression analysis, the baseline oestradiol levels of each
woman were correlated with her serum LH response to SC kis-
speptin-54 at the 3 doses tested. The results suggest there was a
highly significant relationship between baseline oestradiol and
mean LH for the 03 and 10 nmol/kg/h groups as shown in
Table 2 (regression coefficients and P-value for the change in
mean LH for a 100 pmol/l rise in baseline oestradiol: 025,
P = 026, vehicle; 175, P = 024, 01 nmol/kg/h; 083,
P = 003, 03 nmol/kg/h; 100, P = 003, 10 nmol/kg/h). The
positive regression coefficients imply that higher values of base-
line oestradiol were associated with higher LH values in the 2
highest doses tested. For the 10 nmol/kg/h group, a 100pmol/l
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Fig. 2 Effects on serum LH during vehicle and SC infusions of kisspeptin-54 in healthy women during the early follicular phase of the menstrual cycle.
Collated results from all participants in response to 8-h infusions of vehicle and SC kisspeptin-54 at 01, 03 and 10 nmol/kg/h doses. (a) shows the
mean serum LH results for each time point (from all 4 participants) during the 8-h study presented as a time profile. (b) is a graphical representation
of the mean LH over the study period as shown in (a). Black line and bar, vehicle; green line and bar, kisspeptin-54 01 nmol/kg/h; blue line and bar,
kisspeptin-54 03 nmol/kg/h; red line and bar, kisspeptin-54 10 nmol/kg/h. Data are mean  SEM. N = 4/group. Blue***, P < 0001 for SC
kisspeptin-54 03 nmol/kg/h vs vehicle; red ***, P < 0001 for SC kisspeptin-54 10 nmol/kg/h vs vehicle.
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Fig. 3 Effects on serum FSH during infusions of vehicle and SC kisspeptin-54 in healthy women during the early follicular phase of the menstrual
cycle. Mean serum FSH was collated from all participants after an 8-h infusion of either vehicle or SC kisspeptin-54 at 01, 03 and 10 nmol/kg/h
doses. (a) shows the mean serum FSH results for each time point (from all 4 participants) during the 8-h study presented as a time profile. (b) is a
graphical representation of the mean serum FSH over the study period shown in (a). Black line and bar, vehicle; green line and bar, kisspeptin-54
01 nmol/kg/h; blue line and bar, kisspeptin-54 03 nmol/kg/hr; red line and bar, kisspeptin-54 10 nmol/kg/h. Data are mean  SEM. N = 4/group.
Green *, P < 005 for SC 01 nmol/kg/h kisspeptin-54 vs vehicle; blue ***, P < 0001 for SC kisspeptin-54 03 nmol/kg/h vs vehicle; red ***, P < 0001
for SC kisspeptin-54 10 nmol/kg/h vs vehicle.
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rise in baseline oestradiol was associated with a 10 IU/l increase
in LH.
Discussion
This proof of concept study shows that SC administration of
kisspeptin is a viable option for future administration to stimu-
late gonadotrophin release in women. In this study, kisspeptin
had a greater effect on LH compared to FSH release at the doses
tested. This is consistent with previous studies in humans which
show that kisspeptin administration has greatest effects on LH
release with smaller effects on FSH release.14,19 Testing higher
doses of SC infusion of kisspeptin in the future would be useful
to establish the full dosing range and efficacy of this approach
for therapeutic potential.
Oestradiol may be an important determinant of LH response
to kisspeptin. In vitro studies have shown that in GnRH neu-
ronal cell lines oestradiol enhanced GnRH secretion in response
to kisspeptin administration.15,16 In hypothalamic ERa-positive
GT1-7 cells, it was shown that oestradiol upregulated the expres-
sion of the kisspeptin gene.22 In mice, kisspeptin has been
shown to stimulate GnRH neuronal activity and oestradiol fur-
ther enhances kisspeptin-induced GnRH neuronal activity.23
Guerriero et al. administered kisspeptin-10 into the hypothala-
mus of pubertal female rhesus monkeys and directly measured
GnRH production. They showed that ovariectomised pubertal
rhesus monkeys not receiving oestradiol replacement produced
little GnRH in response to kisspeptin when compared with
ovariectomised and oestradiol replaced rhesus monkeys.17 The
differences in response to kisspeptin over the ovulatory cycle in
animals24,25 and in humans9,14,19 may also be closely related to
oestradiol levels. Oestradiol can both negatively and positively
affect the axis depending on the phase of the menstrual cycle.26
These in vitro and in vivo animal studies suggest that oestradiol
is an important determinant of LH response to kisspeptin. Thus,
we compared baseline oestradiol levels with the LH response to
SC kisspeptin infusion at 3 different doses. We showed that a kis-
speptin infusion given at the 2 highest doses of 03 and 10 nmol/
kg/h showed the greatest correlation between baseline oestradiol
and LH response to kisspeptin. This suggested that at these doses
the higher the baseline oestradiol, the better the response to kis-
speptin. In fact, we have shown for the first time that a 100pmol/
l rise in baseline oestradiol resulted in a 10 IU/l rise in LH in
response to a SC infusion of 10 nmol/kg/h kisspeptin-54.
During the menstrual cycle, the response to kisspeptin is
greatest in the preovulatory phase when there are high oestradiol
levels.9,14,19 Of note subject 1 had higher than average baseline
oestradiol levels than would be expected for the early follicular
phase of the menstrual cycle. Her levels were more in keeping
with late follicular phase levels; however, she did not have an
exaggerated response to kisspeptin-54 that is usually seen in the
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Fig. 4 Individual effects on serum LH and FSH during 8-h infusions of vehicle and SC kisspeptin-54 for each participant. Individual time profiles from
each participant 1–4 are presented showing the effects on serum LH (a–d) and FSH (e–h) during infusions of vehicle and SC kisspeptin-54 01, 03 and
10 nmol/kg/h in healthy women during the early follicular phase of the menstrual cycle. Infusions started at t = 0 min and continued for 8-h until
t = 480 min, 10 minutely blood sampling was conducted from t = 0 min. Black circles, vehicle; green circles, kisspeptin-54 01 nmol/kg/h; blue circles,
kisspeptin-54 03 nmol/kg/h; red circles, kisspeptin-54 10 nmol/kg/h.
Table 2. Effects of baseline oestradiol on LH response to kisspeptin-54
administration. Linear regression analysis was used to determine whether
there was an association between baseline oestradiol and the LH
response to SC kisspeptin-54 at 3 doses (01, 03 and 10 nmol/kg/h)
and vehicle, when administered to healthy women in the early follicular
phase of the menstrual cycle. The regression coefficients and confidence
intervals presented represent the change in mean LH for a 100pmol/l
increase in baseline oestradiol
Group Coefficient (95% CI) P-value
Vehicle 025 (072, 023) 026
01 nmol/kg/h kisspeptin-54 175 (485, 136) 024
03 nmol/kg/h kisspeptin-54 083 (012, 153) 003
10 nmol/kg/h kisspeptin-54 100 (011, 189) 003
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late follicular, preovulatory phase of the menstrual cycle.19
Therefore, her oestradiol levels are likely to represent individual
variation rather than another phase of the menstrual cycle.
In summary, our data show that SC administration of kis-
speptin is a potential option for future administration to stimu-
late gonadotrophin release in women to treat reproductive
disorders. In addition our data suggest that baseline oestradiol
levels may be an important determinant of the gonadotrophin
response to kisspeptin treatment in women in the follicular
phase of the menstrual cycle. Thus, suggesting that if kisspeptin
is to be used therapeutically that it may be beneficial to replace
the low oestradiol levels of patients in order to obtain the opti-
mal response from kisspeptin administration. However, further
studies are required to establish the correct dose and duration of
treatment using SC kisspeptin infusion that causes a rise in
gonadotrophins and to confirm that oestradiol supplementation
improves the response to kisspeptin.
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